Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quoin Pharmaceuticals Ltd. (QNRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, and its filings offer detailed insight into clinical development plans, financing structures, governance decisions and risk factors relevant to investors.
Among the most informative documents for QNRX are its periodic reports and current reports on Form 8-K. Recent 8-K filings describe key events such as private placement financings involving American Depositary Shares, pre-funded warrants and multiple series of warrants tied to milestones for the lead asset, QRX003, including pivotal trial outcomes and potential FDA approval. Other 8-Ks outline regulatory milestones, including Orphan Drug Designation and Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome, as well as corporate actions like equity incentive plan approvals, changes in executive leadership and amendments to the company’s articles of association.
For users interested in the clinical and regulatory trajectory of Quoin’s programs, filings referenced to press releases detail the status of late-stage pivotal trials for QRX003, investigator-led pediatric studies and the development of topical rapamycin delivery technologies targeting microcystic lymphatic malformations and venous malformations. These documents also include the company’s cautionary statements about forward-looking information, highlighting uncertainties around clinical trial results, regulatory approvals, funding needs and operational risks.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the core points of complex agreements, equity incentive plans, financing terms and clinical disclosures without reading every page of the original document. In addition, the filings page makes it easier to monitor governance items such as compensation policies, lock-up agreements and shareholder meeting results, all of which can influence the risk–reward profile of QNRX for market participants.
Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs). On February 4, 2026, he was awarded options to acquire 21,709 ADSs at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The options vest over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Langer beneficially owns 21,709 derivative securities directly.
Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant. On February 4, 2026, he was awarded a Share Option (Right to Buy) covering 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals, Ltd. at an exercise price of $7.37 per ADS.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Sember holds 8,141 derivative securities directly.
Quoin Pharmaceuticals reported that director Natalie Leong received a grant of share options for 12,211 American Depositary Shares (ADSs) on February 4, 2026. The options have an exercise price of $7.37 per ADS and expire on February 4, 2036. Each ADS represents 35 ordinary shares of the company.
The option vests over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Leong holds 12,211 derivative securities directly.
Quoin Pharmaceuticals, Ltd. received an amended Schedule 13G showing that Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico together beneficially own 3,271,100 Ordinary Shares, representing 10.6% of the class as of the reported basis.
The stake is held through American Depositary Shares and warrants, including 93,460 ADSs, pre-funded warrants to acquire 81,212 ADSs and ordinary warrants to acquire 484,848 ADSs. The warrants are subject to a 9.9% beneficial ownership cap and are not currently exercisable. The filers state the securities are not held to change or influence control of Quoin.
Stonepine Capital Management, LLCQuoin Pharmaceuticals, Ltd. It indirectly holds 3,271,100 Ordinary Shares, which are represented by 93,460 American Depositary Shares, with each ADS equal to 35 Ordinary Shares.
Through an affiliated limited partnership, Stonepine also indirectly holds pre-funded warrants exercisable at any time for 81,212 ADS, plus Series H, I, J and K warrants, each covering 121,212 ADS at stated exercise prices. These securities are held for the benefit of partnership investors, and the filers disclaim beneficial ownership beyond their pecuniary interests.
Quoin Pharmaceuticals, Ltd. received a major shareholder disclosure showing that Aberdeen Group plc and its affiliate abrdn Inc. beneficially own 75,000 American Depositary Shares, representing 8.94% of this class. These ADSs each represent thirty-five ordinary shares.
The filing states that Aberdeen Group plc and abrdn Inc. share both voting and dispositive power over all 75,000 ADSs, with no sole authority reported. The holders certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Quoin Pharmaceuticals.
Quoin Pharmaceuticals Ltd. filed a Form 8-K describing a key regulatory step for its lead drug candidate QRX003, a late-stage topical treatment for the rare skin disorder Netherton Syndrome. The company has submitted an application to the Saudi Food and Drug Authority for Breakthrough Medicine Designation, a program intended to speed development, review and potential availability of medicines for serious conditions with high unmet need. Quoin believes QRX003 meets all SFDA eligibility criteria and states that, if the designation is granted, regulatory review could be accelerated and patient access in Saudi Arabia could begin as early as the second half of 2026. QRX003 already holds Orphan Drug and Pediatric Rare Disease designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency. The drug is being tested in two late-stage pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half of 2026. Subject to successful results, Quoin plans to submit a New Drug Application in the United States and other territories in late 2026 or early 2027. The company also reports that, as of January 20, 2026, it had 1,616,179 American Depositary Shares outstanding, each representing thirty-five ordinary shares.
Quoin Pharmaceuticals Ltd. is registering up to 10,045,455 American Depositary Shares (ADSs) for resale by investors who participated in an October 2025 private placement.
These ADSs include shares already issued and shares underlying pre-funded and ordinary warrants, and the company states that issuing all of them could significantly increase the ADSs in the public market. The ADSs covered by this prospectus that are not currently outstanding, including 1,968,939 Pre-Funded ADSs and 8,036,364 Ordinary Warrant ADSs, represent approximately 1,193% of the 838,976 ADSs outstanding as of November 3, 2025, so existing holders could experience substantial dilution.
Quoin will not receive proceeds from shareholder resales, but it could receive up to $88.7 million if all Ordinary Warrants are exercised for cash, which it plans to use for general corporate purposes, including advancing its rare-disease pipeline led by QRX003 for Netherton Syndrome and related orphan-designated programs.
Quoin Pharmaceuticals, Ltd. reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor, in a Form 4 filing. The grant covers an option to buy 10,330 American Depositary Shares (ADSs) at an exercise price of $19.36 per ADS, with each ADS representing thirty-five ordinary shares of Quoin. The option was approved by the company’s Compensation Committee on December 1, 2025 and expires on December 1, 2035.
The option vests over four years, with 20% of the ADSs vesting on each of December 1, 2026, 2027 and 2028, and the remaining 40% vesting on December 1, 2029. This filing reflects an equity-based component of the CFO’s compensation, designed to align her interests with long-term shareholder value.
Quoin Pharmaceuticals Ltd. reported that its Compensation Committee approved new standard forms of stock option award agreements for directors and executive officers under the company’s 2025 Equity Incentive Plan. These agreements are designed to allow a range of vesting schedules and terms within what the plan permits. If a grantee dies or becomes disabled, unvested options are forfeited, while vested options may be exercised for up to one year, subject to their stated expiration date. If a grantee is terminated for cause, all options, whether vested or unvested, are terminated and may be subject to recoupment by the company. For terminations for other reasons, unvested options are forfeited and vested options generally remain exercisable for up to three months, but not beyond their original expiration date.